Esperion Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of over 13.1 million shares, representing 5.08% of Esperion Therapeutics' common stock.
NASDAQ
Wasatch Advisors LP has filed a Schedule 13G, reporting beneficial ownership of 1,930,185 shares of Esperion Therapeutics Inc. common stock, representing 0.7% of the class.
NASDAQ
Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G reporting an 8.15% beneficial ownership stake in Esperion Therapeutics, Inc.
NASDAQ
Wasatch Advisors LP has reported beneficial ownership of 15,768,897 shares, representing 6.1% of the outstanding common stock of Esperion Therapeutics Inc.
NASDAQ
The Vanguard Group reported a 0% beneficial ownership in Esperion Therapeutics Inc. common stock following an internal corporate realignment.
NASDAQ
Two Seas Capital LP, along with its general partner and chief investment officer, reported a 4.7% passive beneficial ownership stake in Esperion Therapeutics, Inc. as of September 30, 2025.
NASDAQ
Wasatch Advisors LP has filed an Amendment No. 6 to Schedule 13G, disclosing its beneficial ownership of 3.5% of Esperion Therapeutics Inc. common stock.
NASDAQ
Two Seas Capital LP and affiliates have disclosed a 5% beneficial ownership stake in Esperion Therapeutics, Inc. common stock.
NASDAQ
Wasatch Advisors LP has filed an Amendment No. 5 to Schedule 13G, disclosing a 5.5% beneficial ownership stake in Esperion Therapeutics, Inc. as of March 31, 2025.
NASDAQ
BB Biotech AG, through its wholly-owned subsidiary Biotech Target N.V., has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.89973% of Esperion Therapeutics, Inc.'s common stock as of March 4, 2025.
NASDAQ
BB Biotech AG and its wholly-owned subsidiary, Biotech Target N.V., have reported a continued beneficial ownership of 5.0% in Esperion Therapeutics, Inc. common stock as of December 31, 2024.